Pharma researchers are tasked with organizing disparate data, which detracts from time spent understanding disease mechanisms and enabling the development of more effective drugs. Paradigm4 is tackling this issue with a new platform based on a novel approach to data organization and elastic computing. Even companies with small budgets can access this amazing computational power at a very cost-effective price. — Marilyn Matz and Zach Pitluk, Ph.D.
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
